Full history for every metric is available with a Kvantra account
Synlab AG (SYAB.DE)
Key financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 1,808 | 1,906 | 2,621 | 3,765 | 3,251 | 2,635 | 2,615 |
| Operating profit | €m | 117 | 137 | |||||
| Net profit | €m | -51 | -122 | 38 | 625 | 151 | 92 | 89 |
| EPS reported | € | 0.42 | 0.40 | |||||
| Operating cashflow per share | € | 1.65 | 1.65 | |||||
| Capex per share | € | 0.57 | 0.57 | |||||
| FCF per share | € | 1.08 | 1.08 | |||||
| Free cash flow | €m | 237 | 255 | |||||
| Net debt | €m | 658 | 624 | |||||
| Book value equity | €m | 2,340 | 2,372 | |||||
| Book value per share | € | 10.59 | 10.45 | |||||
| Number of shares | m | 220.96 | 227.06 | |||||
| DPS (TTM paid) | € | 0.33 | 0.00 |
Financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 27.19 | - | |||||
| P/B LTM | x | 1.07 | 1.02 | |||||
| P/S LTM | x | 0.95 | 0.93 | |||||
| P/FCF LTM | x | 10.59 | 9.53 | |||||
| EV/EBITDA LTM | x | 9.36 | 6.32 | |||||
| EV/Sales LTM | x | 1.46 | 1.17 | |||||
| Earnings Yield LTM | % | 3.68% | 3.80% | |||||
| FCF Yield | % | 9.44% | 10.49% | |||||
| Quality | ||||||||
| ROE | % | 3.94% | 10.58% | |||||
| ROIC | % | 1.84% | 1.84% | |||||
| Operating margin | % | 4.45% | 4.45% | |||||
| Gross margin | % | 21.63% | 21.63% | |||||
| FCF/Sales | % | 8.99% | 8.99% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -38.24% | - | |||||
| Sales Growth YoY | % | -18.93% | -9.57% | |||||
| Net Income Growth YoY | % | -38.77% | - | |||||
| FCF Growth | % | -49.74% | -16.51% | |||||
| Operating Profit Growth | % | -74.09% | -75.29% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 3.07% | 0.00% | |||||
| Dividend Growth | % | 0.00% | - | |||||
| Payout Ratio | % | 83.38% | 0.00% | |||||
| FCF/Debt | x | 0.15 | 0.16 | |||||
| Net Debt/EBITDA | x | 3.26 | 3.26 | |||||
| EBIT/Net interest | x | 1.09 | 1.09 | |||||
| Net debt/market cap | % | 26.24% | 25.69% | |||||
| Net debt/Equity | x | 0.28 | 0.26 | |||||
| Gross debt/equity | x | 0.67 | 0.65 | |||||
Company overview
SYNLAB AG delivers extensive clinical laboratory and medical diagnostic services to a diverse clientele, including insurance providers, hospitals, pharmacies, national health organizations, private doctors, clinics, patients, governmental bodies, and corporations, primarily within Europe. The company's offerings include specialized COVID-19 testing, alongside a full range of medical and veterinary diagnostic solutions. Its vast operational network encompasses approximately 500 laboratories and 1,800 blood collection centers, spanning 36 countries across four continents. Established in 1998, SYNLAB AG's corporate headquarters are located in Munich, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Synlab AG (SYAB.DE)
SYNLAB AG delivers extensive clinical laboratory and medical diagnostic services to a diverse clientele, including insurance providers, hospitals, pharmacies, national health organizations, private doctors, clinics, patients, governmental bodies, and corporations, primarily within Europe. The company's offerings include specialized COVID-19 testing, alongside a full range of medical and veterinary diagnostic solutions. Its vast operational network encompasses approximately 500 laboratories and 1,800 blood collection centers, spanning 36 countries across four continents. Established in 1998, SYNLAB AG's corporate headquarters are located in Munich, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free